Download
Upload.pdf 779,13KB
WeightNameValue
1000 Titel
  • Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients
1000 Autor/in
  1. Owusu Sekyere, Solomon |
  2. Port, Kerstin |
  3. Deterding, Katja |
  4. Cornberg, Markus |
  5. Wedemeyer, Heiner |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-02-18
1000 Erschienen in
1000 Quellenangabe
  • 9(4):486-496
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1177/2050640620976991 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259286/ |
1000 Ergänzendes Material
  • https://onlinelibrary.wiley.com/doi/10.1177/2050640620976991#support-information-section |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • INTRODUCTION: The risk of hepatocellular carcinoma persists in some patients despite achieving sustained virologic response with current interferon-free direct-acting antiviral therapy for hepatitis C. The subject of an even higher carcinoma risk in this context has been reported and is currently being debated. The quest for understanding this paradox relative to the dynamics of inflammatory biomarkers in cirrhosis patients receiving antiviral therapy thus remains a subject of importance. OBJECTIVE: Here, we aimed at evaluating the effects of direct-acting antiviral therapy-induced hepatitis C cure on plasmatic markers of systemic inflammation measured before, during and after treatment. Specifically, soluble immune mediator phenotype associations that impact the odds of hepatocellular carcinoma development and the related changes that arise upon direct-acting antiviral-mediated hepatitis C clearance in cirrhosis patients was investigated. METHODS: Employing multiplex technology that measured up to 91 circulating biomarker proteins, we profiled the plasma soluble immune mediator concentrations of cirrhosis patients who developed posttreatment hepatocellular carcinoma and their respective negative controls, before and after direct-acting antiviral treatment. RESULTS: Elevated pretherapy concentrations of specific soluble immune mediators including MCP-3, GDNF, CDCP1, IL-17C, IL-17A, signalling lymphocytic activation family 1, CCL11, FGF-5, LIF-R, interleukin 10 (IL-10), IL-10RA, IL-15RA, beta NGF, CCL28, CCL25 and NT-3 distinguished patients who developed posttreatment hepatocellular carcinoma relative to those that did not. Particularly, GDNF, FGF-5 and IL-15RA displayed independent predictive biomarker attributes for delineating carcinoma emergence regardless of de novo or recurrence groupings. Upon successful therapy, the elevated pretherapy soluble immune mediator establishment of the patients who eventually developed hepatocellular carcinoma stayed largely unperturbed whereas a panel of some 38 soluble immune mediators in the posttherapy carcinoma-free patients experienced significant ameliorations. CONCLUSIONS: These results have considerable implications for delineating potential hepatocellular carcinoma emergence before initiating direct-acting antiviral therapy for hepatitis C in cirrhosis patients. They provide preliminary contribution to unravelling cases where the benefit of direct-acting antiviral therapies would be superior to the risk of developing carcinoma.
1000 Sacherschließung
lokal chemokines
lokal soluble immune mediators
lokal cytokines
lokal hepatocellular carcinoma
lokal direct-acting antivirals
lokal hepatitis C virus cirrhosis
gnd 4262007-7 Hepatitis C
lokal interferon-free therapy
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-1893-5475|https://orcid.org/0000-0001-8338-3227|https://d-nb.info/gnd/132829037|https://orcid.org/0000-0002-9141-8001|https://orcid.org/0000-0003-2906-0480
1000 Label
1000 Förderer
  1. Deutsche Forschungsgemeinschaft |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. SFB900 "Chronic Infections: Microbial Persistence and its Control"; SFB 738
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Deutsche Forschungsgemeinschaft |
    1000 Förderprogramm SFB900 "Chronic Infections: Microbial Persistence and its Control"; SFB 738
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6432109.rdf
1000 Erstellt am 2022-03-10T11:06:52.328+0100
1000 Erstellt von 323
1000 beschreibt frl:6432109
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet 2022-03-31T07:46:20.471+0200
1000 Objekt bearb. Thu Mar 31 07:46:04 CEST 2022
1000 Vgl. frl:6432109
1000 Oai Id
  1. oai:frl.publisso.de:frl:6432109 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source